Summary
Although the number of reports on mitomycin C (MMC) pharmacokinetics is increasing, data on possible relations between clinical parameters and pharmacokinetics are usually lacking. The present report concenrns the results of a detailed study on this subject in 35 patients receiving MMC, either as a single agent or as a part of combination chemotherapy. MMC concentrations were determined by HPLC. T1/2β varied from 23 to 78 min, VD from 11 to 48 l/m2, Cltot from 12 to 42 l/h per m2, and AUC from 138 to 1221 μg/h per l, confirming previously reported data. Infusion time, cholestasis, and urinary pH did not influence the pharmacokinetic data. There were no relations between other clinical data and pharmacokinetics, nor between AUC and bone marrow toxicity. An interaction between MMC and furosemide could not be excluded, but there was no interaction with other comedication. Consecutive pharmacokinetics in 6 patients showed consistent results. Because renal impairment does not alter MMC pharmacokinetics and renal excretion is not a major route of elimination, it is suggested that renal impairment does not call for dose adjustment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Buice RG, Niell HB, Sidhu P, Gurley BJ (1984) Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. Cancer Chemother Pharmacol 13:1–4
Crooke ST, Bradner WT (1976) Mitomycin C:A review. Cancer Treat Rev 3:121–139
Fujita H (1971) Comparative studies on the blood level, tissue distribution, excretion and inactivation of anticancer drugs. Jap J Clin Oncol 12:151–162
den Hartigh J, van Oort WJ, Bocken MCYM, Pinedo HM (1981) High performance liquid chromatography determination of the antitumor agent mitomycin C in human blood plasma. Anal Chim Acta 127:47–53
den Hartigh J, McVie JG, van Oort WJ, Pinedo HM (1981) Pharmacokinetics of mitomycin C in humans. Cancer Res 43:5017–5021
den Hartigh J, Voortman G, van Oort WJ, Pinedo HM, Weenen H (1983) Binding of mitomycin C to red blood cells and plasma proteins. Proc ECCO 2:15
den Hartigh J, Voortman G, van Oort WJ, Weenen H, Pinedo HM (1985) Handling of biological samples in the analysis of the anti-neoplastic drug mitomycin C. J Pharmacol Biomed Anal 3:417–423
van Hazel GA, Scott M, Rubin J (1983) Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep 67:805–810
Hu E, Howell SB (1983) Pharmacokinetics of intraarterial mitomycin C in humans. Cancer Res 43:4474–4477
Kerpel-Fronius S, Verweij J, Stuurman M, Lelieveld P, Pinedo HM (1986) Pharmacokinetics of mitomycin C in Wistar rats in single agent and combination chemotherapy (in press)
Philips FS, Schwartz HS, Sternberg SS (1960) Pharmacology of mitomycin C, I, Toxicity and pathologic effects. Cancer Res 20:1354–1361
Schilcher RB, Young JD, Ratanatharatorn V, Karanes C, Baker LH (1984) Clinical pharmacokinetics of high dose mitomycin C. Cancer Chemother Pharmacol 13:186–190
Schwartz HS, Philips FS (1961) Pharmacology of mitomycin C-II. Renal excretion and metabolism by tissue homogenates. J Pharmacol Exp Ther 133:335–342
Wakaki S, Marumo H, Tomioka K (1958) Isolation of new fraction of antitumor mitomycins. Antibiot Chemother 8:228–240
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Verweij, J., den Hartigh, J., Stuurman, M. et al. Relationship between clinical parameters and pharmacokinetics of mitomycin C. J Cancer Res Clin Oncol 113, 91–94 (1987). https://doi.org/10.1007/BF00389973
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00389973